Why Cheaper Humira Alternatives Face Resistance
Hosted by Sarah Mitchell & James Carter
Show Notes
Adalimumab biosimilars cut NHS spend by over 50% while treating more patients. NOR-SWITCH and subsequent trials consistently show switching from reference biologic to biosimilar is safe. Sarah Mitchell and James Carter explain the regulatory science, the nocebo effect, and how the biosimilar dividend is being reinvested into newer therapies.
Downloads
Cite This Article
Team TLSFE. Why cheaper humira alternatives face resistance. The Life Science Feed. Published June 1, 2026. Updated June 1, 2026. Accessed June 1, 2026. https://thelifesciencefeed.com/podcast/2026-06-01/why-cheaper-humira-alternatives-face-resistance.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Podcast Disclaimer
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.